Phunware forms JV with AnyPlace MD Box to provide contact tracing and COVID-19 testing to government agencies and health systems

Phunware Inc (NASDAQ:PHUN) announced Friday it has formed a joint venture with AnyPlace MD Box (APMDBox) to provide contact tracing, telehealth, COVID-19 testing, and logistics support to government agencies and health systems. APMDBox has worked for five years to develop and patent a robust, mobile diagnostic and health platform. Its cloud-based, automated contact tracing software and predictive modeling provides real-time data for confirmed positive maps, potential exposure mapping and hotspot emergence, according to a statement. “As a company, we decided in March to focus our efforts on fighting COVID-19 to help America hold its course. Our existing team and business model was perfectly suited to pivot into an almost immediate COVID-19 end-to-end solution,” said D. Shane Stevens, Co-CEO of APMDBox. READ: Phunware partners with Sirius Computer Solutions to revamp mobile user experiences in healthcare “Over the past 17 years we have helped mobilize over 1 million members of the United States military in pre-deployment screenings. Now we are doubling down our efforts to provide COVID-19 and SARS-CoV2 antibody testing,” Stevens added. Phunware’s Multiscreen-as-a-Services (MaaS) platform provides category-defining mobile experiences and capabilities that enable a digital front door for healthcare providers, allowing them to better engage with patients throughout the continuum of care. With this new joint venture, APMDBox will gain access to Phunware’s MaaS Mobile Engagement software - enabling broadcast, geofence and bluetooth low energy (BLE) proximity push notifications, alerts and messages - as well as Phunware’s MaaS Analytics and Business Intelligence software, to capture key usage information across an end-to-end COVID-19 solution.  Key features of the combined solution include, but are not limited to: Free daily symptom monitoring COVID-19 polymerase chain reaction (PCR) tests SARS-CoV-2 serologic antibody testing Production of up to 6 million antibody tests per day A state-of-the-art, patented telehealth platform, complete with built-in Artificial Intelligence to support the interpretation of tests Remote positive patient monitoring Historical geotracing for any positive patient to enable potential exposure and proximity alerts from one month or longer (pending approval by US Food and Drug Administration) “We are dedicated to providing our customers with the very best resources and technology to effectively respond during these challenging times,” said Phunware CEO Alan Knitowski. “This joint solution with AnyPlace MD enables hospitals and local governments to respond quickly to COVID-19 by layering contact tracing on top of Phunware's proven Healthcare Solution on mobile.” The Austin-based company’s stock recently traded up by 7.7% to $1.32 a share in New York. Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham